Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1484/j.arihs.5.110297 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The mysterious case of missing lymphocytes: a cautionary tale of inter-institutional variability in outcomes of lung dissociation protocols.
Am J Physiol Lung Cell Mol Physiol
January 2025
Dept. of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.
Rigor and reproducibility are vital to scientific advancement. It is unclear whether a protocol optimized for tissue dissociation in one institution performs well universally. Here, we share our brand-new lab's experience with inter-institutional variability that led to the discovery that a protocol optimized for murine lung dissociation at Boston University (BU) fails to reproduce similar CD4 T cell, CD8 T cell, and B cell outcomes at the University of Michigan at Ann Arbor (U-M).
View Article and Find Full Text PDFA field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery.
Neuro Oncol
December 2024
Department of Neurological Surgery, Mayo Clinic; Rochester, MN, USA.
Background: While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However, the impact of key variables to consider in longitudinal CSF samples for monitoring biomarker discovery, including anatomical location and post-surgical changes, remains unknown.
Methods: Aptamer-based proteomics was performed on 147 CSF samples from 74 patients, 71 of whom had grade 2-4 astrocytomas or grade 2-3 oligodendrogliomas.
Classification of schwannomas and the new naming convention for "neurofibromatosis-2": Genetic updates and international consensus recommendation.
Neuroradiol J
January 2025
Department of Neuroradiology, Mayo Clinic, USA.
Despite their similar nomenclature, Neurofibromatosis type 1 (NF1) and "Neurofibromatosis type 2" are discrete and clinically distinguishable entities. The name of "neurofibromatosis type 2" has been changed to NF2-related schwannomatosis, to reflect the fact that neurofibromas do not occur in this syndrome and therefore the name "Neurofibromatosis" is factually incorrect. Furthermore, multiple schwannomas, a hallmark feature of NF2, can also occur in patients with mutations in genes including SMARCB1 and LZTR1, all exhibiting overlapping clinical features.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: Whole genome methylation sequencing (WGMS) in blood identifies extensive differential DNA methylation between persons who are cognitively unimpaired (CU) and those with late-onset dementia due to Alzheimer's disease (AD). Here we investigate differentially methylated positions (DMPs) in persons with mild cognitive impairment (MCI) compared to persons with and without AD.
Method: WGMS data quantified DNA methylation levels at 25,406,945 CpG loci in 382 blood samples from 99 persons with MCI, 109 persons with AD and 174 cognitively unimpaired persons in the Wisconsin Alzheimer's Disease Research Center (WADRC) and the Wisconsin Registry for Alzheimer's Prevention (WRAP).
Biomarkers.
Alzheimers Dement
December 2024
Framingham Heart Study, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Background: Recent technological advancements have revolutionized our approach to healthcare, enabling us to harness the potential of smartphones and wearables to collect data that can be used to characterize Alzheimer's disease (AD) heterogeneity and to develop digital biomarkers. Our focus is to create comprehensive cross-domain digital datasets and establish an infrastructure that allows for seamless data sharing. Central to accelerating the potential of digital biomarkers for more accurate and early detection is privacy-protecting data access, which when combined with deep molecular phenotyping, will enhance our understanding of the biological mechanisms underlying clinical expression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!